| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,420 | -1,599 |
| Depreciation and amortization | 260 | 141 |
| Common stock-based compensation and expenses, net | 1,182 | 452 |
| Other non-cash items | -1,079 | -24 |
| Accounts receivables, net | 7 | 53 |
| Inventory | -17 | -11 |
| Deposits and advances | -220 | -183 |
| Claims and advances | -8 | 0 |
| Accounts payable | -252 | 51 |
| Accrued and other liabilities | -506 | -599 |
| Operating lease asset | -85 | -32 |
| Operating lease liability | -5 | -2 |
| Net cash used in operating activities | -3,497 | -1,407 |
| Purchase of property, plant, and equipment | 37 | 8 |
| Sale of property, plant, and equipment | 679 | 702 |
| Investment in short-term investment | 25 | - |
| Acquisition and development of intangible assets | 411 | 114 |
| Net cash from (used) in investing activities | 206 | 580 |
| Repayment of a long-term loan | - | -1 |
| Net proceeds from the issuance of common stock | 3,963 | 852 |
| Repayment of long-term loan | 2 | - |
| Net cash provided by financing activities | 3,961 | 851 |
| Effects of exchange rate changes on cash and cash equivalents | 30 | 25 |
| Net increase in cash and cash equivalents | 700 | 49 |
| Cash and cash equivalents at beginning of period | 405 | - |
| Cash and cash equivalents at end of period | 1,105 | - |
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)